CN120173119B - 一种补体抑制剂的开发和应用 - Google Patents

一种补体抑制剂的开发和应用

Info

Publication number
CN120173119B
CN120173119B CN202510392268.2A CN202510392268A CN120173119B CN 120173119 B CN120173119 B CN 120173119B CN 202510392268 A CN202510392268 A CN 202510392268A CN 120173119 B CN120173119 B CN 120173119B
Authority
CN
China
Prior art keywords
seq
antibody
nucleic acid
variable region
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202510392268.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN120173119A (zh
Inventor
徐刚
陈博
王常玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Lingyue Biomedical Technology Co ltd
Chengdu Kangnuohang Biomedical Technology Co ltd
Keymed Biomedical Technology Chengdu Co ltd
Shanghai Konoya Pharmaceutical Technology Co ltd
Original Assignee
Beijing Lingyue Biomedical Technology Co ltd
Chengdu Kangnuohang Biomedical Technology Co ltd
Shanghai Konoya Pharmaceutical Technology Co ltd
Connaught Biomedical Technology Chengdu Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Lingyue Biomedical Technology Co ltd, Chengdu Kangnuohang Biomedical Technology Co ltd, Shanghai Konoya Pharmaceutical Technology Co ltd, Connaught Biomedical Technology Chengdu Co ltd filed Critical Beijing Lingyue Biomedical Technology Co ltd
Priority to CN202510392268.2A priority Critical patent/CN120173119B/zh
Publication of CN120173119A publication Critical patent/CN120173119A/zh
Application granted granted Critical
Publication of CN120173119B publication Critical patent/CN120173119B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN202510392268.2A 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用 Active CN120173119B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510392268.2A CN120173119B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202510392268.2A CN120173119B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用
CN202011485792.8A CN114634575B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202011485792.8A Division CN114634575B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用

Publications (2)

Publication Number Publication Date
CN120173119A CN120173119A (zh) 2025-06-20
CN120173119B true CN120173119B (zh) 2025-09-30

Family

ID=81944764

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202510392268.2A Active CN120173119B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用
CN202510392209.5A Active CN120173118B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用
CN202011485792.8A Active CN114634575B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用
CN202180085328.6A Pending CN116648464A (zh) 2020-12-16 2021-12-15 一种补体抑制剂的开发和应用

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510392209.5A Active CN120173118B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用
CN202011485792.8A Active CN114634575B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用
CN202180085328.6A Pending CN116648464A (zh) 2020-12-16 2021-12-15 一种补体抑制剂的开发和应用

Country Status (9)

Country Link
US (1) US20240067751A1 (cg-RX-API-DMAC7.html)
EP (1) EP4265641A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023554081A (cg-RX-API-DMAC7.html)
KR (1) KR20230118941A (cg-RX-API-DMAC7.html)
CN (4) CN120173119B (cg-RX-API-DMAC7.html)
AU (1) AU2021398697A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202507A1 (cg-RX-API-DMAC7.html)
IL (1) IL303794A (cg-RX-API-DMAC7.html)
WO (1) WO2022127834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7690612B2 (ja) * 2021-06-08 2025-06-10 シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド 抗masp-2抗体及びその使用
JP2024524440A (ja) * 2021-06-30 2024-07-05 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規抗masp-2抗体
WO2023103789A1 (zh) * 2021-12-10 2023-06-15 舒泰神(北京)生物制药股份有限公司 特异性识别masp2的抗体及其应用
EP4643878A2 (en) * 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460195A (zh) * 2006-04-03 2009-06-17 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的疾病的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2465534B1 (en) * 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
EP3150635A3 (en) * 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
DK2694108T3 (en) * 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
AU2013201779B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
JP2019533423A (ja) * 2016-07-06 2019-11-21 シャンハイ ファーマエクスプローラー カンパニー,リミティド BLyS抗体及びその製造方法と応用
EP3836965A4 (en) * 2018-06-22 2022-04-20 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460195A (zh) * 2006-04-03 2009-06-17 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的疾病的方法

Also Published As

Publication number Publication date
IL303794A (en) 2023-08-01
KR20230118941A (ko) 2023-08-14
CN120173118B (zh) 2025-09-16
CN120173119A (zh) 2025-06-20
CN114634575B (zh) 2025-04-11
EP4265641A1 (en) 2023-10-25
CN120173118A (zh) 2025-06-20
US20240067751A1 (en) 2024-02-29
CA3202507A1 (en) 2022-06-23
CN114634575A (zh) 2022-06-17
WO2022127834A1 (zh) 2022-06-23
CN116648464A (zh) 2023-08-25
AU2021398697A1 (en) 2023-07-20
JP2023554081A (ja) 2023-12-26

Similar Documents

Publication Publication Date Title
CN120173118B (zh) 一种补体抑制剂的开发和应用
TWI796328B (zh) B7-h3抗體、其抗原結合片段及其醫藥用途
WO2019238012A1 (zh) 可以阻断CD47和SIRPa相互作用的抗体及其应用
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
CN102652139B (zh) Pcsk9拮抗剂
JP7317016B2 (ja) 抗lrp5/6抗体及び使用方法
JP6067756B2 (ja) マトリックスメタロプロテイナーゼ9に対する抗体
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
CN110914304A (zh) Cd96抗体、其抗原结合片段及医药用途
US20220162338A1 (en) Anti-fxi/fxia antibody and use thereof
CN113906053B (zh) 抗cea抗体及其应用
US20240309113A1 (en) Novel anti-masp-2 antibodies
JP2022539212A (ja) 単一特異性抗Frizzled抗体および使用の方法
CN116601296A (zh) 一种新型肿瘤衔接器治疗药物的开发和应用
JP2018509894A (ja) Pcsk9抗体、及び医薬組成物とその使用
CN113631579B (zh) 组织纤溶酶原激活物抗体及其使用方法
RU2418004C2 (ru) Модуляторы активатора фактора роста гепатоцитов
CN110114370A (zh) 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段
JPWO2015125904A1 (ja) 新規抗ヒトpai−1抗体
CN111196849A (zh) 抗硬骨素抗体、其抗原结合片段及其医药用途
JP2016525519A (ja) 凝血促進活性を誘発することができる組織因子経路インヒビターのn末端部分を認識する抗体
WO2024022478A1 (zh) 结合大麻素受体cb1的抗体及其用途
CN118496364A (zh) uPARAP特异性结合蛋白及其制备方法和应用
HK40052551B (en) Anti-fxi/fxia antibody and use thereof
JP2018082720A (ja) マトリックスメタロプロテイナーゼ9に対する抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250820

Address after: Building D2, No. 18 Bio City Road, Chengdu Tianfu International Bio City, Shuangliu District, Chengdu City, Sichuan Province 610219

Applicant after: Connaught Biomedical Technology (Chengdu) Co.,Ltd.

Country or region after: China

Applicant after: Beijing Lingyue Biomedical Technology Co.,Ltd.

Applicant after: Shanghai Konoya Pharmaceutical Technology Co.,Ltd.

Applicant after: Chengdu kangnuohang Biomedical Technology Co.,Ltd.

Address before: Building D2, No. 18 Bio City Road, Chengdu Tianfu International Bio City, Shuangliu District, Chengdu City, Sichuan Province 610219

Applicant before: Connaught Biomedical Technology (Chengdu) Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 610000 Sichuan Province Chengdu City Xin Qu Ke Yuan Nan Lu 88 Hao Building 12 C1 Incubation Building 4th Floor Room 406

Patentee after: Keymed Biomedical Technology (Chengdu) Co.,Ltd.

Country or region after: China

Patentee after: Beijing Lingyue Biomedical Technology Co.,Ltd.

Patentee after: Shanghai Konoya Pharmaceutical Technology Co.,Ltd.

Patentee after: Chengdu kangnuohang Biomedical Technology Co.,Ltd.

Address before: Building D2, No. 18 Bio City Road, Chengdu Tianfu International Bio City, Shuangliu District, Chengdu City, Sichuan Province 610219

Patentee before: Connaught Biomedical Technology (Chengdu) Co.,Ltd.

Country or region before: China

Patentee before: Beijing Lingyue Biomedical Technology Co.,Ltd.

Patentee before: Shanghai Konoya Pharmaceutical Technology Co.,Ltd.

Patentee before: Chengdu kangnuohang Biomedical Technology Co.,Ltd.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 610000 Sichuan Province, Chengdu City, High-tech Development Zone, Ke Yuan South Road No. 88, Building 12, C1 Incubation Building, 4th Floor, Room 406

Patentee after: Keymed Biomedical Technology (Chengdu) Co.,Ltd.

Country or region after: China

Patentee after: Beijing Lingyue Biomedical Technology Co.,Ltd.

Patentee after: Shanghai Konoya Pharmaceutical Technology Co.,Ltd.

Patentee after: Chengdu kangnuohang Biomedical Technology Co.,Ltd.

Address before: 610000 Sichuan Province Chengdu City Xin Qu Ke Yuan Nan Lu 88 Hao Building 12 C1 Incubation Building 4th Floor Room 406

Patentee before: Keymed Biomedical Technology (Chengdu) Co.,Ltd.

Country or region before: China

Patentee before: Beijing Lingyue Biomedical Technology Co.,Ltd.

Patentee before: Shanghai Konoya Pharmaceutical Technology Co.,Ltd.

Patentee before: Chengdu kangnuohang Biomedical Technology Co.,Ltd.